Expression of neuregulin 4 splice variants in normal human tissues and prostate cancer and their effects on cell motility

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 39-49

  Hayes, Nandini V L ^a   Blackburn, Edith ^a   Boyle, Mary M ^b   Russell, Graham A ^c   Frost, Teresa M ^a   Morgan, Byron J T ^a   Gullick, William J ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

^b Preston Hall   (United Kingdom)

^c Pembury Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEU DIFFERENTIATION FACTOR; NEUREGULIN 4; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; FILOPODIUM; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LAMELLIPODIUM; MALE; MOUSE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; PROTEIN FOLDING; PROTEIN FUNCTION; RNA SPLICING; TISSUE DISTRIBUTION; WOUND HEALING;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANIMALS; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MALE; MICE; NEUREGULINS; NIH 3T3 CELLS; PRINCIPAL COMPONENT ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TRANSFECTION;

EID: 79251516427     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0112     Document Type: Article

References (25)

1. Carpenter G & Liao HJ 2009 Trafficking of receptor tyrosine kinases to the nucleus. Experimental Cell Research 315 1556-1566. (doi:10.1016/j.yexcr. 2008.09.027)
2. Citri A & Yarden Y 2006 EGF-ERBB signalling: towards the systems level. Nature Reviews. Molecular Cell Biology 7 505-516. (doi:10.1038/nrm1962)
3. Citri A, Skaria KB & Yarden Y 2003 The deaf and the dumb the biology of ErbB-2 and ErbB-3. Experimental Cell Research 284 54-65. (doi:10.1016/S0014- 4827(02)00101-5)
4. Cohen BD, Green JM, Foy L & Fell HP 1996 HER4-mediated biological and biochemical properties in NIH3T3 cells. Evidence for HER1-HER4 heterodimers. Journal of Biological Chemistry 271 4813-4818. (doi:10.1074/jbc.271.9.4813)
5. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E & Klagsbrun M 1999 Characterisation of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18 2607-2615. (doi:10.1038/sj.onc.1202612)
6. Falls DL 2003 Neuregulins: functions forms and signalling strategies. Experimental Cell Research 284 14-30. (doi:10.1016/S0014-4827(02)00102-7)
7. Hancock ML, Canetta SE, Role LW & Tammage DA 2008 Presynaptic type III neuregulin1-ErbB signalling targets alpha7 nicotinic acetylcholine receptors to axons. Journal of Cell Biology 181 511-521. (doi:10.1083/jcb.200710037)
8. Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC & Yarden Y 1999 Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18 2681-2689. (doi:10.1038/sj.onc.1202631)
9. Hayes NV & Gullick WJ 2008 The neuregulin family of genes and their multiple splice variants in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 205-214. (doi:10.1007/s10911-008-9078-4)
10. Hayes NV, Blackburn E, Smart LV, Boyle MM, Russell GA, Frost TM, Morgan BJT, Baines AJ & Gullick WJ 2007 Identification and characterisation of novel splice variants of neuregulin 4 in prostate cancer. Clinical Cancer Research 13 3147-3155. (doi:10.1158/1078-0432.CCR-06-2237)
11. Hayes NV, Newsam RJ, Baines AJ & Gullick WJ 2008 Characterisation of the membrane-associated products of the neuregulin 4 gene. Oncogene 27 715-720. (doi:10.1038/sj.onc.1210689)
12. Hynes NE, Horsch K, Olayioye MA & Badache A 2001 The ErbB receptor tyrosine kinase family as signal integrators. Endocrine-Related Cancer 8 151-159. (doi:10.1677/erc.0.0080151)
13. Jones FE 2008 HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 247-258. (doi:10.1007/s10911-008-9076-6)
14. Jones JT, Akita RW & Sliwkowski MX 1999 Binding specificities and affinities of egf domains for ErbB receptors. FEBS Letters 447 227-231. (doi:10.1016/S0014-5793(99)00283-5)
15. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M & Elenius K 2000 A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival and chemotaxis. Journal of Biological Chemistry 275 8641-8649. (doi:10.1074/jbc.275.12.8641)
16. Kita YA, Barff J, Luo Y, Wen D, Brankow D, Hu S, Prigent SA, Gullick WJ & Nicolson M 1994 NDF/Heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Letters 349 139-143. (doi:10.1016/0014-5793(94)00644-X)
17. Kurokawa K & Matsuda M 2005 Localised RhoA activation as a requirement for the induction of membrane ruffling. Molecular Biology of the Cell 16 4294-4303. (doi:10.1091/mbc.E04-12-1076)
18. Montero JC, Roderiguez-Barrueco R, Ocana A, Diaz-Roderiguez E, Esparis-Ogando A & Pandiella A 2008 Neuregulins and cancer. Clinical Cancer Research 14 3237-3241. (doi:10.1158/1078-0432.CCR-07-5133)
19. Rajkumar T, Stamp G, Hughes CM & Gullick WJ 1996 c-erbB-3 protein expression in ovarian cancer. Clinical Molecular Pathology 49 199-202. (doi:10.1136/mp.49.4.M199)
20. Ritch PA, Carroll SL & Sontheimer H 2003 Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. Journal of Biological Chemistry 278 20971-20978. (doi:10.1074/jbc.M213074200)
21. Srinivasan R, Poulsom R, Hurst HC & Gullick WJ 1998 Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. Journal of Pathology 185 236-245. (doi:10.1002/(SICI)1096-9896(199807)185:3〈236::AID-PATH118〉3.0.CO;2-7)
22. Stein RA & Staros JV 2006 Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evolutionary Biology 6 79. (doi:10.1186/1471-2148-6-79)
23. Steinthorsdottir V, Stefanson H, Ghosh S, Birgisdottir B, Bjornsdottir S, Fasquel AC, Olafsson O, Stefansson K & Gulcher J 2004 Multiple novel transcription initiation sites for NRG1. Gene 342 97-105. (doi:10.1016/j.gene. 2004.07.029)
24. Sundvall M, Iljin K, Kipinin S, Sara H, Kallioniemi OP & Elenius K 2008 Role of ErbB4 in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 259-268. (doi:10.1007/s10911-008-9079-3)
25. Yarden Y & Sliwkowski MX 2001 Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology 2 127-137. (doi:10.1038/35052073)